Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals.
IgE-mediated type-I allergy is generally considered to be a hypersensitivity reaction to foreign antigens, and it is believed that self-antigens do not evoke this type of allergy. We report here, for the first time, that non-mutated self-antigen peptides identified as tumor-rejection antigen peptides recognized by HLA class I-restricted and tumor-specific cytotoxic T lymphocytes (CTLs) elicited a type-I allergy in the majority of healthy individuals. Peptide-specific IgE was detectable in sera from certain cases, although the levels did not always correlate with those of type-I allergy. Repeated vaccinations of nonallergic peptides derived from the same antigens possessing allergic peptides resulted in the suppression of both allergic peptide-specific IgE responses and type-I allergy, providing evidence for a new approach to the development of peptide-based desensitization.
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Japan.
S
S
Ohkouchi
A
A
Yamada
N
N
Imai
T
T
Mine
K
K
Harada
S
S
Shichijo
Y
Y
Maeda
Y
Y
Saijo
T
T
Nukiwa
K
K
Itoh
D000328:Adult; D019943:Amino Acid Substitution; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D001323:Autoantibodies / Q000096:biosynthesis / Q000097:blood; D001324:Autoantigens / Q000235:genetics / Q000276:immunology*; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology*; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D012882:Skin Tests; D013045:Species Specificity; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology
D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D007074:Immunoglobulin G; D022223:Vaccines, Subunit; D007073:Immunoglobulin E